低剂量分次放疗作为替莫唑胺化疗增敏剂治疗复发性间变性星形细胞瘤和胶质母细胞瘤:单臂1/2期试验
该单臂1/2期试验评估低剂量分次放疗(LDFRT)联合替莫唑胺治疗复发性高级别胶质瘤的安全性和疗效。 preclinical显示LDFRT的化疗增敏作用优于2 Gy。30例患者中,1年总生存率为34.5%,未达到主要生存终点,但77%出现假性进展且与改善的总生存相关。
要点
- LDFRT联合替莫唑胺在复发性高级别胶质瘤中安全且耐受良好。
- 1年总生存率34.5%,未达到预设的主要生存终点。
- 77%患者出现假性进展,且与改善的总生存显著相关。
核心结论
- LDFRT联合替莫唑胺在复发性高级别胶质瘤挽救性再照射中安全且耐受良好。
- 虽然主要生存终点未达到,但低剂量下高假性进展率支持低剂量放疗超敏性由化疗增敏和潜在免疫调节介导的原理。
研究设计与样本
- 临床部分为单臂1/2期试验,纳入标准治疗后复发的复发性高级别胶质瘤患者。
- 放疗方案为0.5 Gy每日两次,同步替莫唑胺在28天周期的第1至5天给药,共6周期,后续辅助替莫唑胺6周期。
- 1期主要终点为急性血液学毒性,2期主要终点为1年总生存率,其80%置信区间下限需大于28.6%(历史对照)。
主要发现
- 2013年至2021年共入组30例患者,80%为复发性胶质母细胞瘤,90%为ECOG 0-1。
- 在具有分子数据的患者中,61%为MGMT启动子甲基化,23%为IDH突变。
- 中位放疗剂量为30 Gy(范围28.5-30 Gy),中位随访9.5个月(范围0.1-66.3个月)。
- 1年总生存率为34.5%(95%CI 20.9-57.0;80%CI下限=24.8%)。
- 77%患者出现假性进展(中位剂量10 Gy;范围6-30 Gy),与无假性进展者相比总生存改善(HR 0.12;95%CI 0.03-0.40;P<.01)。
关键数值与推荐
- 2期主要终点1年总生存率的80%置信区间下限需大于28.6%,实际为24.8%,未达到。
- 假性进展与改善的总生存相关,HR为0.12(95%CI 0.03-0.40;P<.01)。
临床怎么用
- 对于复发性高级别胶质瘤患者,LDFRT联合替莫唑胺可作为挽救性再照射的安全选择。
- 治疗中出现的假性进展可能提示生存获益,需与真性进展鉴别。
局限性
- 单臂设计,无随机对照,样本量较小(30例)。
- 主要生存终点未达到预设标准。
- 假性进展的高发生率可能影响疗效评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical and clinical studies suggest low-dose fractionated radiation therapy (LDFRT) is a chemopotentiator in several solid tumors. We evaluated chemopotentiation of temozolomide with LDFRT in glioblastoma and brain metastatic lung cancer cell lines, followed by a phase 1/2 trial assessing the safety/efficacy of LDFRT with concurrent/adjuvant temozolomide in patients with recurrent high-grade gliomas (HGGs). METHODS AND MATERIALS: Preclinical-The temozolomide-potentiating effect of LDFRT was tested in glioblastoma and brain metastatic lung cancer cell lines with real-time cell electronic sensing system and flow cytometry. Clinical-Patients with recurrent HGG following standard-of-care chemoradiation therapy and adjuvant temozolomide were enrolled. Radiation therapy consisted of 0.5 Gy twice daily fractions with concurrent temozolomide on days 1 to 5 of a 28-day cycle for 6 cycles, and adjuvant temozolomide for 6 cycles. Magnetic resonance imaging was performed every 2 months after initiating LDFRT. The phase 1 primary endpoint was acute hematologic toxicity. The phase 2 primary endpoint was 1-year overall survival (OS), with a lower bound of 80% confidence interval > 28.6% (historical control). Secondary endpoints included pseudoprogression incidence. RESULTS: Preclinical-LDFRT-mediated temozolomide potentiation appears more effective than 2 Gy-mediated potentiation. Clinical-Thirty patients were enrolled from 2013 to 2021; 80% had recurrent glioblastoma and 90% were Eastern Cooperative Oncology Group 0-1. Among patients with molecular data, 61% were O-6-methylguanine-DNA methyltransferase-methylated and 23% were isocitrate dehydrogenase-mutant. Median RT dose was 30 Gy (range, 28.5-30 Gy). Median follow-up was 9.5 months (range, 0.1-66.3 months). One-year OS was 34.5% (95% confidence interval [CI], 20.9-57.0; lower bound of 80% CI = 24.8%). 77% experienced pseudoprogression (median dose 10 Gy; range, 6-30 Gy), corresponding with improved OS (HR, 0.12; 95% CI, 0.03-0.40; P < .01) versus no pseudoprogression. CONCLUSIONS: Preclinical work demonstrates the chemopotentiating effect of LDFRT. In our clinical trial, LDFRT with temozolomide was safe and well tolerated in patients with recurrent HGG receiving salvage reirradiation. Although the primary survival endpoint was not achieved, high pseudoprogression rates at low radiation doses support the principle of low-dose radiation hypersensitivity mediated by chemopotentiation and potentially immune-modulation.
引用
- Lin T, Ke S, Hu C, et al. Low-Dose Fractionated Radiation Therapy as a Chemopotentiator of Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma: A Single-Arm Phase 1/2 Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41138784. doi:10.1016/j.ijrobp.2025.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。